BRAF and colorectal carcinoma: An exploratory study by Elez et al. suggested that the RNF43 mutation in BRAF-mutated patients is a favorable predictor of response to BRAF inhibitors in BRAF-mutated microsatellite stable (MSS) CRC patients.